摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-溴-2-(2-甲氧基乙氧基)苯 | 109417-60-9

中文名称
1-溴-2-(2-甲氧基乙氧基)苯
中文别名
——
英文名称
1-bromo-2-(2-methoxyethoxy)benzene
英文别名
o-bromo(2-methoxyethoxy)benzene;1-bromo-2-(2-methoxy-ethoxy)-benzene;2-bromo-1-(2-methoxyethoxy)-benzene;(2-methoxyethoxy)bromobenzene
1-溴-2-(2-甲氧基乙氧基)苯化学式
CAS
109417-60-9
化学式
C9H11BrO2
mdl
MFCD09934824
分子量
231.089
InChiKey
YQNVKSQBACJWHD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    12
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    18.5
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险性防范说明:
    P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    室温、密封、干燥

SDS

SDS:5a3b4dc21edb3ce844bf36bed84ac30e
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-溴-2-(2-甲氧基乙氧基)苯正丁基锂硼酸三乙酯 作用下, 以 乙醚 为溶剂, 反应 2.17h, 以23.5%的产率得到2-(2-甲氧基乙氧基)苯硼酸
    参考文献:
    名称:
    Hydrogen bonds in phenylboronic acids with polyoxaalkyl substituents at ortho-position
    摘要:
    Phenylboronic acids with polyoxaalkyl substituents at ortho position were synthesized from the corresponding bromides. Structures in solid state, determined by single crystal X-ray diffraction, reveal the presence of inter- and intramolecular hydrogen bonds. Presence of several oxygen atoms in oxaalkyl chains enables the formation of intramolecular hydrogen bonds by B(OH)(2) group with different oxygen centers which lead to the formation of bifurcated hydrogen bonds. Investigated compounds were characterized by H-1, C-13, B-11 and O-17 NMR spectroscopy in solution. Assignment of H-1 and C-13 signals was made on the basis of HSQC and HMBC spectra. O-17 NMR spectra show that in acetonitrile solution hydrogen bonds with solvent molecules are predominant. (C) 2008 Elsevier B.V. All rights reserved.
    DOI:
    10.1016/j.molstruc.2008.12.006
  • 作为产物:
    参考文献:
    名称:
    JURSIC, BRANKO, TETRAHEDRON, 44,(1988) N 5, 1553-1558
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Pyrrolo-pyridine kinase modulators
    申请人:Arnold D. William
    公开号:US20060030583A1
    公开(公告)日:2006-02-09
    The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.
    本发明提供了新型吡咯-吡啶激酶调节剂以及利用这些新型吡咯-吡啶激酶调节剂治疗由激酶活性介导的疾病的方法。
  • FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF
    申请人:GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD.
    公开号:US20180208604A1
    公开(公告)日:2018-07-26
    Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.
    揭示的区域融合环嘧啶化合物,以及中间体、制备方法、组合物及其用途。融合环嘧啶化合物是如下式I所示的化合物,其为互变异构体、对映异构体、顺反异构体、药学上可接受的盐、代谢物、代谢前体或其前药,上述化合物用于制备用于预防、缓解或治疗免疫系统疾病、自身免疫疾病、细胞增殖性疾病、过敏性疾病和心血管疾病中的一种或多种的药物,且该化合物对Janues激酶、FGFR激酶、FLT3激酶和Src家族激酶具有强烈的抑制作用。
  • [EN] DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS<br/>[FR] INHIBITEURS DES CANAUX SODIQUES DE TYPE DIHYDROBENZOXAZINE ET TÉTRAHYDROQUINOXALINE
    申请人:AMGEN INC
    公开号:WO2013122897A1
    公开(公告)日:2013-08-22
    The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
    本发明提供了式I的化合物或其药学上可接受的盐,这些化合物是电压门控钠通道的抑制剂,特别是Nav 1.7。这些化合物对于治疗可通过抑制钠通道治疗的疾病,如疼痛障碍,是有用的。还提供了含有本发明化合物的药物组合物。
  • [EN] AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES AMINO-SUBSTITUÉS UTILISÉS COMME INHIBITEURS DES CANAUX SODIQUES
    申请人:ALMIRALL SA
    公开号:WO2016170009A1
    公开(公告)日:2016-10-27
    The present invention relates to novel aminoindazolyl derivative compounds of Formula(I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7 AND to compositions containing said derivatives.
    本发明涉及一种新型氨基吲唑基衍生物化合物的公式(I),所述化合物在治疗特定由调节电压门控钠通道,特别是Nav1.7介导的疾病中的应用,以及含有该衍生物的组合物。
  • Rigidifying Cation-Tunable Nickel Catalysts Increases Activity and Polar Monomer Incorporation in Ethylene and Methyl Acrylate Copolymerization
    作者:Babak Tahmouresilerd、Dawei Xiao、Loi H. Do
    DOI:10.1021/acs.inorgchem.1c02888
    日期:2021.12.20
    species in solution, respectively. The nickel complexes were competent catalysts for ethylene homopolymerization and copolymerization, with activities up to 3.8 × 103 and 8.1 × 10 kg mol–1 h–1, respectively. In reactions of ethylene with methyl acrylate (1.0 M), the addition of Li+ to Ni3 led to a 5.4-fold enhancement in catalyst activity and a 1.9-fold increase in polar monomer incorporation in comparison
    在这项研究中,我们合成并表征了两种具有构象刚性双膦单氧化物配体的镍配合物,其中一种具有邻甲氧基苯基 ( Ni2 ),另一种在 P 上具有邻(2-甲氧基乙氧基)苯基 ( Ni3 ) 取代基。 =O 部分。我们使用Ni3进行了金属结合研究,发现它与 Li +和 Na + 的反应最有可能分别在溶液中产生 1:1 和 1:1/2:1 的镍:碱物质。镍配合物是乙烯均聚和共聚的有效催化剂,活性高达 3.8 × 10 3和 8.1 × 10 kg mol –1 h –1, 分别。在乙烯与丙烯酸甲酯 (1.0 M) 的反应中,在优化条件下,与单独使用Ni3相比,向Ni3添加 Li +导致催化剂活性提高 5.4 倍,极性单体掺入增加 1.9 倍。与报道的用于乙烯和丙烯酸甲酯共​​聚的其他镍催化剂的比较表明,我们的镍碱催化剂与迄今为止开发的一些最有效的镍基体系相比具有竞争力。
查看更多